Table 1.
Performance of antigens in discriminating recurrent from Non-recurrent ovarian cancer patients at 2 different diagnosis intervals
| First post diagnosis interval (Method A) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Antigen | TP | FN | FP | TN | Sensitivity | Specificity | PPV | NPV |
| 02Mecl_BP4_Pl_Dl 1 < −0.193 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| 02Mecl_BP4_P3_Al 1 ≥ 0.288 | 5 | 0 | 0 | 5 | 100 | 100 | 100.0 | 100.0 |
| Mecl_lA3 < 0.135 | 5 | 0 | 0 | 5 | 100 | 100 | 100.0 | 100.0 |
| Mecl_lB4 < 0.123 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| Mecl_2D7 ≥ −0.75 | 5 | 0 | 1 | 4 | 100 | 80 | 83.3 | 100.0 |
| Mecl_2G9 ≥ 0.197 | 5 | 0 | 1 | 4 | 100 | 80 | 83.3 | 100.0 |
| Mecl_3A7 ≥ −0.105 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| Mecl_3D5 ≥ −0.425 | 5 | 0 | 1 | 4 | 100 | 80 | 83.3 | 100.0 |
| Mecl_3Gl ≥ −0.687 | 5 | 0 | 1 | 4 | 100 | 80 | 83.3 | 100.0 |
| Mecl_4B5 <0.331 | 5 | 0 | 0 | 5 | 100 | 100 | 100.0 | 100.0 |
| Mecl_4B7 < −0.271 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| Mecl_4F8 < 0.355 | 5 | 0 | 1 | 4 | 100 | 80 | 83.3 | 100.0 |
| Mecl_4G9 < −0.538 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| Mecl_5A3 < 0.083 | 5 | 0 | 2 | 3 | 100 | 60 | 71.4 | 100.0 |
| Mecl_5A7 < −0.437 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| Mecl_5C7 < −0.414 | 5 | 0 | 0 | 5 | 100 | 100 | 100.0 | 100.0 |
| Mecl_5H10 < −0.767 | 4 | 1 | 0 | 5 | 80 | 100 | 100.0 | 83.3 |
| CA125 ≥ 35 | 0 | 5 | 0 | 5 | 0 | 100 | NaN* | 50.0 |
|
| ||||||||
| First post diagnosis interval (Method B) | ||||||||
|
| ||||||||
| Antigen | TP | FN | FP | TN | Sensitivity | Specificity | PPV | NPV |
|
| ||||||||
| 02Mec 1 _BP4_P2_A2 ≥ −0.017 | 4 | 0 | 0 | 3 | 100 | 100 | 100 | 100 |
| 02Mecl_BP4_P3_F10 ≥ −0.335 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| Mecl.lEl ≥ 0.202 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100 |
| Mecl_4B5 < −0.039 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100 |
| Mecl_4C10 ≥ −0.128 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| Mecl_4D9 < −0.254 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| Mecl_4F2 ≥ 0.607 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| Mecl_5A7 < −0.241 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100 |
| Mecl_5C7 < −0.094 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100 |
| Mecl_5H6 ≥ 0.28 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| P111_BP4_P4_F6 ≥ −0.12 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| P156_BP4_P2_H3 < 0.486 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
| P87_BP3_P2_C10 ≥ 0.083 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75 |
|
| ||||||||
| Second post diagnosis interval (Method C) | ||||||||
|
| ||||||||
| Antigen | TP | FN | FP | TN | Sensitivity | Specificity | PPV | NPV |
|
| ||||||||
| Mecl_2B3 ≥ 0.297 | 4 | 1 | 0 | 4 | 80 | 100 | 100 | 80.0 |
| Mecl_2H5 ≥ 0.084 | 4 | 1 | 0 | 4 | 80 | 100 | 100 | 80.0 |
| Mecl_3A12 < −0.062 | 4 | 1 | 0 | 4 | 80 | 100 | 100 | 80.0 |
| Mecl_3D7 < 0.044 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100.0 |
| Mecl_3F9 ≥0.116 | 3 | 2 | 0 | 4 | 60 | 100 | 100 | 66.7 |
| Mecl_3Gl 1 ≥ −0.134 | 4 | 1 | 0 | 4 | 80 | 100 | 100 | 80.0 |
| Mecl_4E8 < −0.389 | 4 | 1 | 0 | 4 | 80 | 100 | 100 | 80.0 |
| Mecl_5C12 ≥ −0.426 | 5 | 0 | 0 | 4 | 100 | 100 | 100 | 100.0 |
| MH2.1 ≥ −0.37 | 5 | 0 | 0 | 3 | 100 | 100 | 100 | 100.0 |
| P156_BP4_P2_C5 < 0.233 | 4 | 1 | 0 | 3 | 80 | 100 | 100 | 75.0 |
| P156_BP4_P2_H3 < 0.151 | 5 | 0 | 0 | 4 | 100 | 100 | 100 | 100.0 |
NOTE: Method A: Normalized values at first post diagnosis interval for each patient were used for the statistical analyses(see Materials and Methods).
Methods B and C: The normalized values at first and second post diagnosis intervals for each patient were subtracted from their values closest to their time of diagnosis and statistical analyses were performed (see Materials and Methods).
TP = True positive. FN = False negative. FP = False positive. TN = True negative. PPV = Positive predictive value. NPV = Negative predictive value.